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Several herpesviruses contain open reading frames (ORFs) that encode potential homologs of eucaryotic
genes. Equine herpesvirus 2 (EHV-2) is a gammaherpesvirus related to other lymphotropic herpesviruses such
as herpesvirus saimiri and Epstein-Barr virus. The E1 ORF of EHV-2, a G protein-coupled receptor homolog,
shows 31 to 47% amino acid identity with known CC chemokine receptors. To investigate whether E1 may
encode a functional receptor, we cloned the E1 ORF and expressed it in stably transfected cell lines. We report
here the identification of the CC chemokine eotaxin as a functional ligand for the EHV-2 E1 receptor.
Chemokines are likely to play a role in the regulation of immune functions in equine hosts during EHV-2
infection and, via interaction with E1, may affect viral replication and/or escape from immune responses.
Viruses often integrate in their own genomes several cellular
genes involved in the control of cell growth and differentiation
and/or in the regulation of immune functions. These “pirated”
genes may confer a replicative advantage to infecting viruses by
interfering with cellular functions and by subverting the host
immune system through molecular mimicry (2, 16, 22). Her-
pesviruses and poxviruses frequently contain in their genome
host-derived genes homologous to immunoregulatory genes,
such as cytokines and cytokine receptors (4, 28), or to cell cycle
regulatory molecules such as bcl-2 and cyclins (4, 40, 49).
The gamma subfamily of herpesviruses generally replicates
in lymphoblastoid, epithelial, and fibroblastic cells, with the
former group of cells being the preferred site of latency. This
subfamily is further divided into the g1 genus (typified by the
Epstein-Barr virus [EBV]) and the g2 genus (e.g., herpesvirus
saimiri [HVS] that infects nonhuman primates and human
herpesvirus 8 [HHV-8] associated with Kaposi’s sarcoma).
Over the past decade chemokines have been shown to play
an important role in inflammation, hematopoiesis, and angio-
genesis, as well as in atherosclerosis, tumor growth, and several
other pathological conditions (27, 34). Chemokines represent a
family of structurally related molecules whose conserved cys-
teine residues define the two major subgroups of CXC and CC
chemokines (7). Such molecules interact with seven transmem-
brane-spanning receptors and signal through the activation of
heterotrimeric G proteins, thus modulating several cellular
functions (58).
Several herpesviruses have been found to encode chemo-
kines and/or chemokine receptor genes that may affect host
immune responses or virus tissue tropism and/or dissemina-
tion, thus contributing to viral pathogenesis. A number of
herpesvirus-encoded chemokine receptors have been reported
to be functional and able to bind known chemokines (29, 38).
Thus, HVS open reading frame (ORF) 74, also known as
ECRF3, is homologous to the CXCR2 receptor and binds and
signals in response to Groa, NAP-2, and interleukin-8 (IL-8)
(3). Similarly, the cytomegalovirus (CMV) ORF US28, homol-
ogous to CCR1, binds MIP-1a, MIP-1b, MCP-1, and RANTES
and signals in response to these ligands (20, 41). HHV-8 ORF
74 has been extensively studied and shown to be a CXC che-
mokine receptor homolog which, interestingly, while it exhibits
constitutive signalling, may be further activated by Groa and
IL-8 and inhibited by SDF-1, IP-10, and Mig. This receptor is
expressed in Kaposi’s sarcoma lesions and appears to act as a
viral oncogene, inducing cell proliferation, transformation, and
tumor angiogenesis (6, 8, 21).
Equine herpesvirus 2 (EHV-2) is a lymphotropic gamma-
herpesvirus with a high prevalence rate in horse populations
(1). The complete genome of EHV-2 (strain 86/67) has been
determined, demonstrating that it is more similar to g2 her-
pesviruses (e.g., HVS) than g1 herpesviruses (e.g., EBV) (52).
While its role as a pathogen is still unclear, EHV-2 infection
has been implicated in immunosuppression in foals, in con-
junctivitis, and in respiratory inflammatory processes and poor
racing performance (14, 30, 39, 47). EHV-2 has been isolated
from peripheral blood mononuclear cells of foals (39), from
the respiratory tracts of animals with clinical signs of disease,
and from draining lymph nodes, potentially representing the
main viral reservoirs. Moreover, the virus has been detected, at
lower frequency, in both the peripheral and central nervous
systems, mostly in the trigeminal ganglion, a putative site for
EHV-2 latency (47). In addition, EHV-2 has been proposed to
act as a trans-activating factor, which may either trigger or
upregulate EHV-1 and EHV-4 expression from a latent state
(44, 59). EHV-2 contains 79 ORFs that encode 77 distinct
molecules, several of which show striking homology to cellular
genes. These include an IL-10 homolog (E7); two proteins
which interact with apoptosis-signalling pathways, v-FLIP (E8)
(55) and v-CARMEN (E10) (54); and three putative G pro-
tein-coupled receptors (GPCRs). EHV-2 ORF 74 is colinear
and conserved (ca. 20% homology) with the corresponding
ORF of HVS (53). This ORF is a characteristic feature of the
g2 genus, being conserved in the majority characterized to date
(namely, HVS, EHV-2, HHV-8, and murine gammaherpesvi-
rus 68 (MHV-68) (57), with the exception of alcephaline her-
pesvirus type 1 (18). ORF E6 is predicted to encode a protein
with seven transmembrane domains and other features char-
acteristic of GPCRs (53) and is homologous to the BILF1
ORF of EBV (16). The third GPCR homolog, ORF E1, is the
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only identified diploid ORF within the EHV-2 genome, being
encoded within the terminal direct repeat elements.
The E1 ORF shows the highest degree of homology with
cellular chemokine receptors compared with other viral
GPCRs and, among viral products, is conserved most closely
with the human CMV ORF US28 (53). Its structural related-
ness to this class of molecules suggests that it may also share
biological responses of classical chemokine receptors. We
therefore investigated whether E1 may be functionally active in
response to chemokines when expressed in eucaryotic cell lines
and found that this receptor responds to eotaxin in both cal-
cium mobilization and chemotaxis assays, suggesting a role of
chemokines during EHV-2 infection.
MATERIALS AND METHODS
Recombinant proteins. Human I-309 was purchased from R&D Systems (Min-
neapolis, Minn.) and human eotaxin, RANTES, MIP-1a, MIP-1b, MCP-3,
BCA-1, IP-10, and Mig were from PeproTech (London, United Kingdom).
Molecular cloning of the E1 ORF into expression vectors. Both nucleotide and
protein sequences corresponding to known chemokine receptors were used for
comparative analysis of GenBank and other databases to search for homologous
receptors. Our bioinformatic screening of nonredundant databases identified the
EHV-2 E1 ORF (accession number U20824) (53) as a putative chemokine
receptor.
The entire E1 ORF was amplified from EHV-2 (strain 86/67) genomic DNA
(the kind gift of A. J. Davison, University of Glasgow) by PCR with primers
containing EcoRI restriction sites at their 59 ends. The primer sequences were
59-CAG AAT TCA TGG CAA CCA CTT CAG C-39 (forward primer) and
59-CAG AAT TCC ATG CTG GTG GTC CAT C-39 (backward primer). After
an initial denaturation step (5 min at 94°C), PCR was performed with AmpliTaq
DNA polymerase (Perkin-Elmer/Roche, Branchburg, N.J.) for a total of 35
cycles (45 s at 94°C, 1 min at 60°C, and 1 min at 72°C), with a final extension at
72°C for 10 min. PCR products were digested with EcoRI, gel purified, and
subcloned in the pcDNA3 expression vector (Invitrogen, Groningen, The Neth-
erlands) by standard procedures.
Creation of stably transfected cell lines. 293 human embryonic kidney (HEK)
cells were grown in Dulbecco modified Eagle medium (DMEM) containing 10%
fetal bovine serum (FBS) and 2 mM glutamine; 300-19 murine pre-B cells were
grown in complete medium (RPMI, 10% FBS, glutamine, and 50 mM b-mer-
captoethanol). Plasmids were transfected into 293 cells by the calcium phosphate
method as previously described (11) and into 300-19 cells by electroporation.
Briefly, 3 3 106 cells/400 ml were mixed with 10 mg of plasmid DNA, incubated
on ice for 10 min, transferred to a 0.4-cm electroporation cuvette, and subjected
to a single pulse at 280 V and 960 mF (Gene Pulser II Apparatus; Bio-Rad
Laboratories, Hercules, Calif.). The electroporated cells were left on ice for 15
min and resuspended in complete medium. At 48 h posttransfection, with both
methods, cells were placed under selection in medium containing 1 mg of G418
(Life Technologies, Inc., Grand Island, N.Y.) per ml for several weeks to gen-
erate stable transfectants.
RNA extraction and RT-PCR analysis. Total RNA was extracted from trans-
fected cells by using the TRIzol Reagent (Life Technologies) according to the
manufacturer’s instructions, digested with RNase-free DNase (Promega, Madi-
son, Wis.) for 1 h at 37°C, and purified. First-strand cDNA was obtained by using
Superscript II reverse transcriptase (RT; Life Technologies) according to the
manufacturer’s instruction. Briefly, 5 mg of total RNA was reverse transcribed in
a 20-ml reaction mixture. Then, 1 ml of the cDNA template was PCR amplified
by using primer pairs and the cycling conditions described above. The same
amount of template was subjected to 25 cycles of PCR amplification by using
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) primers as a control for
normalization. The samples were then run on a 1.2% agarose gel in the presence
of ethidium bromide and detected by using a GelDoc 1000 apparatus (Bio-Rad
Laboratories).
Intracellular [Ca21] measurement. 300-19 cells were loaded with Fluo4-AM
(Molecular Probes, Inc., Eugene, Oreg.) according to the manufacturer’s instruc-
tions, with minor modifications. Briefly, cells (5 3 106/ml) were incubated in
Hanks buffered saline solution without Ca21 and Mg21, supplemented with 10
mM HEPES (pH 7.4), and containing 2.5 mM Fluo4-AM for 40 min at 37°C.
Cells were subsequently washed with Hanks solution and incubated at 37°C for
30 min in Hanks solution containing 10 mM HEPES, 5% FBS, and 2 mM CaCl2
(HHF) to allow for complete fluorochrome de-esterification. Cells where then
washed twice in HHF and resuspended in HHF at 2 3 106 cells/ml. Intracellular
[Ca21] changes were evaluated by using a FACScan cytofluorimeter (Becton-
Dickinson, Mountain View, Calif.) equipped with an argon laser (emission at 488
nm). After basal levels of fluorescence were attained, cells were stimulated with
chemokines (at 100 ng/ml), and the fluorescence increase in the emission spec-
trum of Fluo4 (516 nm) was recorded every 10 s for 3 min. Intracellular [Ca21]
levels were expressed as the fluorescence fold increase, calculated by dividing the
mean fluorescence intensities at each time point of stimulation by the mean
fluorescence intensity recorded at time zero.
Chemotaxis assay. The migration of 293 cells expressing the E1 receptor was
assessed as previously described (10, 46). Briefly, cells were trypsinized, incu-
bated in DMEM–10% FBS for 1 h at room temperature, washed in RPMI
supplemented with 1% bovine serum albumin–25 mM HEPES (migration me-
dium [MM]), and placed in the upper wells of a 48-well chemotaxis chamber
(Neuro Probe, Inc., Cabin John, Md.) at 0.5 3 106 cells/ml in triplicates in a final
volume of 50 ml. Chemokines were placed in the lower wells in a 27-ml volume
of MM. Polyvinylpyrrolidone-free polycarbonate membranes (12-mm pores)
(Costar, Corning Inc., Corning, N.J.) were coated with 20 mg of mouse collagen
type IV (Collaborative Biomedical Product; Becton-Dickinson Labware, Bed-
ford, Mass.) per ml for 2 h at 37°C. The chemotaxis assay was performed for 6 h
at 37°C; the filter was fixed and stained with a Diff-Quik Kit (DADE, Dudingen,
Switzerland), and the cells were counted at 3400 magnification in four randomly
selected fields. Migration indices were calculated by dividing the average number
of cells migrated in the presence of chemokines by the number of cells migrated
in migration medium alone.
RT-PCR analysis of E1 expression in EHV-2-infected cells. Equine embryonic
kidney cell monolayers (1.5 3 106 cells) were infected with approximately 0.01
PFU of EHV2 isolate 33839 (provided by the Animal Health Trust Diagnostic
Services laboratory) per cell and, after infection, maintained in minimal essential
medium containing 5% FBS, glutamine, penicillin, and streptomycin. Cells were
harvested 5 days postinfection, and total RNA was extracted by using the gua-
nidine thiocyanate-based DNA/RNA Isolation Kit (USB, Cleveland, Ohio) ac-
cording to the manufacturer’s instructions. Purification of poly(A)1 RNA from
50 ml of total RNA (#250 mg of total RNA) was performed by using Oligotex
(Qiagen, GmbH) according to the manufacturer’s instructions. RT-PCR analysis
of EHV-2 infected-cell poly(A)1 RNA was performed as follows. First, 5 ml of
poly(A)1 RNA was mixed with 1 ml (40 U) of RNasin (Promega) and 2 ml (200
ng) of Oligo(dT)15 Primer (Promega), heated at 65°C for 5 min, and then
quenched on ice for 2 min. Then, reverse transcription was performed by using
M-MLV Reverse Transcriptase (Promega), and the samples were incubated at
37°C for 60 min, 42°C for 60 min, and 95°C for 5 min. After reverse transcription,
the E1 ORF was amplified by PCR by using the forward primer E1Ef (59-TT
CGA ATT CAC AGT AAA ATG GCA ACC AC-39) and the reverse primer
E1Er (59-T TCG AAT TCA AAT GCG GGT GGG CCC CT-39) as follows. A
5-ml portion of the above RT reaction mixture was subjected to PCR amplifica-
tion by using AmpliTaq DNA Polymerase (Perkin-Elmer). After an initial de-
naturation step (94°C for 4 min), PCR was performed for a total of 33 cycles
(94°C for 30 s, 58°C for 1 min, and 72°C for 2 min), with a final extension at 72°C
for 10 min. Amplified products were run on a 1.5% agarose in 13 TBE gel, and
products were visualized by using ethidium bromide.
RESULTS
Cloning of EHV-2 E1 ORF and generation of cellular trans-
fectants. In an effort to search for new members of the che-
mokine receptor superfamily, we used selected amino acid
sequences corresponding either to complete ORFs or to con-
served regions of these receptors, in order to screen nucleotide
and protein databases of both expressed sequence tags (36)
and nonredundant sequences. This method allowed us to iden-
tify a number of molecules whose predicted sequence matched
GPCRs possibly belonging to the chemokine receptor family.
Among those we chose to characterize, the EHV-2 E1 ORF
was predicted to encode a 383-amino-acid (aa) seven-trans-
membrane protein with significant homology with human CC-
chemokine receptors, specifically, CCR3 (47%), CCR1 (44%),
CCR5 (40%), and CCR8 (35%) (Table 1). In Fig. 1 the amino
acid alignment of E1 and human CCR3 by a CLUSTALW
analysis is shown. Like most GPCRs, the E1 sequence shows
an N-terminal extracellular domain, seven transmembrane re-
gions, three extracellular and intracellular loops, and a C-
terminal cytoplasmic tail. As for most chemokine receptors,
the N-terminal region is poorly conserved and is, in addition,
considerably longer compared to members of the chemokine
receptor family. E1 shows three potential N-linked glycosyla-
tion sites in its N-terminal region (aa 11 to 13, 22 to 24, and 42
to 44) and a protein kinase C (PKC) phosphorylation site in its
third intracellular loop (aa 270 to 272) (Fig. 1).
To characterize the role of E1 as a chemokine receptor, we
cloned the entire E1 ORF, whose DNA was PCR amplified by
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using oligonucleotides based on the viral DNA sequence, into
the pcDNA3 eucaryotic expression vector and, after cell trans-
fection, generated cell lines stably expressing the E1 protein.
Both a lymphoid (300-19) and an epithelial (293/HEK) cell line
were utilized. After G418 selection, total RNA was extracted
from stably transfected cells and subjected to RT-PCR ampli-
fication to verify E1 mRNA expression. As depicted in Fig. 2
(upper panel), 300-19- and 293-transfected cells showed the
expression of a single band of 1,197 bp (lanes 2, 3, and 5)
corresponding to an amplified message containing the entire
E1 ORF and flanking regions in comparison to the control
cells (lanes 1 and 4). PCR amplification of GAPDH, showed in
the lower panel of Fig. 2, was used as a control for normaliza-
tion.
Functional characterization of transfected cells. In order to
demonstrate that E1 may behave as a functional receptor and
to identify its potential agonists, we measured both calcium
mobilization and chemotaxis of E1- and mock-transfected cells
in response to a panel of CC and CXC chemokines. Both
assays are widely utilized for the characterization of chemokine
receptors, since their ligands typically induce such functional
responses in target cells.
We first analyzed 300-19-transfected cells for calcium mobi-
lization in response to chemokines. As shown in Fig. 3, 300-19
E1 cells, loaded with Fluo4, functionally responded to eotaxin
at a concentration of 100 ng/ml. Eotaxin induced an increase in
the intracellular calcium concentration, as measured by Fluo4
fluorescence intensity, after 30 s of chemokine addition, which
reached a twofold increase over background levels and then
declined progressively. By contrast, mock-transfected cells did
not show any change in Fluo4 fluorescence upon eotaxin ad-
dition (Fig. 3), thus identifying eotaxin as a functional ligand
for EHV-2 E1. Conversely, the CC chemokines RANTES,
FIG. 1. Amino acid homology between EHV-2 E1 and human CCR3. Align-
ment was done by using the CLUSTALW program. Two dots denote identities,
whereas single dots indicate conservative substitutions. N-linked glycosylation
(ppp) and PKC phosphorylation (ooo) sites are marked. Gaps (dashes) were
inserted from the program to obtain maximum alignment.
FIG. 2. RT-PCR analysis of E1 mRNA expression in E1-transfected cells.
(Upper panel) A single E1 mRNA transcript (1,197 bp) was detected in two
300-19/E1 bulk transfectants (lane 2 and 3) and 293/E1 (lane 5) cells but not in
300-19/mock (lane 1) and 293/mock (lane 4) cells. (Lower panel) GAPDH
amplification (450 bp) was used for sample normalization.
FIG. 3. Intracellular calcium mobilization in E1-transfected cells. Fluo4-
loaded mock (closed circles)- and E1 (closed squares)-transfected cells were
analyzed by flow cytometry for calcium mobilization after the addition of eotaxin
(100 ng/ml). Results are expressed as the fold increase of Fluo4 mean fluores-
cence intensities compared to the emission at time zero. The data represent the
average (6 the standard error of the mean [SEM]) of four independent exper-
iments.
TABLE 1. Amino acid homology between EHV-2 E1 ORF and
human chemokine receptors
Receptor Identity(%)
Positivitya
(%)
No. of
residues
CCR3 47 63 355
CCR1 44 60 355
CCR2 41 56 374
CCR5 40 56 352
CCR8 35 57 355
CCR4 33 51 360
CCR6 33 47 374
CCR7 31 49 378
CXCR2 29 53 360
CXCR1 29 51 350
CXCR4 27 48 352
a Positivity indicates the amino acid similarity.
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MIP-1a, MCP-3, and I-309 and the CXC chemokines IP-10,
Mig, and BCA-1 induced a barely detectable increase of mean
fluorescence intensities in both mock- and E1-transfected cells
(data not shown).
We then measured the chemotactic responses of 293 cells to
a panel of chemokines in a 48-well microchamber assay. Such
transfectants were chosen for their high level of E1 expression,
as shown in Fig. 2.
Eotaxin was tested in a wide range of concentrations on both
mock- and E1-transfected cells to confirm its activity as a
chemoattractant. As shown in Fig. 4A, eotaxin induced a po-
tent chemotactic response (migration index, 2 to 4) in 293/E1-
transfected cells, with a typical bell-shaped dose-response
curve and maximal activity of agonist at a concentration of 100
to 300 ng/ml. These concentrations did not elicit a chemotactic
response in mock-transfected cells (Fig. 4A). Further, the CC
chemokines RANTES, MIP-1a, MIP-1b, and MCP-3 did not
induce a significant chemotactic response in either mock- or
E1-transfected 293 cells (Fig. 4B).
In conclusion, while eotaxin induced both calcium mobiliza-
tion and chemotaxis in E1 transfectants, RANTES, MIP-1a,
MIP-1b, MCP-3, I-309, BCA-1, IP-10, and Mig did not elicit
functional activation of E1 transfectants in either calcium or
chemotaxis assays.
RT-PCR analysis of E1 expression in EHV-2-infected cells.
In order to confirm that the E1 ORF is transcribed in EHV-
2-infected cells, we determined whether E1 mRNA is ex-
pressed by RT-PCR analysis. Primary equine embryonic kid-
ney cells were infected with a field isolate of EHV-2 and
harvested 5 days postinfection (after the development of sig-
nificant cytopathic effect). Cell lysates were processed for the
preparation of poly(A)1 RNA and analyzed by RT-PCR by
using oligo(dT) to prime cDNA synthesis, followed by PCR
with E1 specific primers. As shown in Fig. 5, E1-specific
mRNA was detected in EHV-2-infected (lane 4) but not in
mock-infected (lane 5) cells. Thus, mRNA of the correct ori-
entation for expression of E1 is transcribed in EHV-2-infected
equine cells.
DISCUSSION
EHV-2 has been found to encode ORFs with significant
homology to cellular immunomodulatory proteins, similarly to
other gammaherpesviruses. These include an IL-10 homolog
(E7) that may be involved in the suppression of antiviral im-
mune functions and three GPCR homologs (ORFs E1, E6, and
74) that potentially interact with cellular chemokines (53). To
date, however, there has been no direct demonstration of ac-
tivity for the proteins encoded by these ORFs or of their gene
expression during infection.
E1 has been identified as a putative CC chemokine receptor
that is highly related to CCR3 (47% identities) and other
chemokine receptors. The high degree of homology shown by
E1 with cellular receptors belonging to this family is striking
compared with other viral GPCRs, which are usually more
distantly related to eucaryotic counterparts, and suggests that
this ORF has been acquired relatively recently. The location of
FIG. 4. Chemotaxis of E1-transfected cells. (A) A range of concentrations of eotaxin (from 10 to 500 ng/ml) was used in a 48-well microchamber migration assay
on mock (shaded columns)- and E1 (dashed columns)-transfected cells. Migration indexes (6 the SEM) are shown, and the data represent the average of three to five
independent experiments. (B) Chemotaxis of mock (shaded columns)- and E1 (dashed columns)-transfected cells in response to 100 ng of several CC chemokines per
ml. Migration indices (6 the SEM) are shown for three to five independent experiments.
FIG. 5. RT-PCR detection of E1 mRNA in EHV-2-infected cells. Virus-
infected cells were probed for the expression of mRNA encoding E1 by RT-PCR
with oligo(dT)-primed cDNA synthesis, followed by PCR amplification with
E1-specific primers. Lanes: 1, kilobase ladder; 2, PCR of EHV-2 DNA template;
3, RT-PCR of poly(A)1 RNA from EHV-2-infected cells in the absence of RT
treatment; 4, RT-PCR of poly(A)1 RNA from EHV-2-infected cells in the
presence of RT treatment; 5, RT-PCR of total RNA from uninfected cells.
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E1 in the viral genome, namely, within the terminal repeat
elements, distal to the “core” blocks of genes conserved with
other gammaherpesviruses, further supports this hypothesis.
Our studies show that the chemokine receptor-like E1 ORF
encodes a functional receptor, since we identified the CC che-
mokine eotaxin as a ligand able to induce both calcium mobi-
lization and chemotaxis in cellular transfectants overexpressing
the E1 protein, whereas a number of other chemokines, either
CC or CXC, were ineffective. Furthermore, we have demon-
strated that mRNA encoding E1 is expressed upon EHV-2
infection of equine cells in tissue culture.
A certain degree of functional redundancy may be hypoth-
esized for chemokine receptors (7), since they often share
common ligands and biological functions (i.e., chemotaxis) and
are distributed on similar leukocyte subpopulations. However,
there are several examples of discrete roles attributed either to
selected ligands (15, 23) or to chemokine receptors (13, 25, 51,
60) by the use of genetically modified mice, as well as the
demonstration of discrete ligand and receptor expression on
leukocyte populations in pathophysiological states (34).
Eotaxin represents a typical example of a “specialized” func-
tion, playing an important role during allergic reactions and
parasitic infections; this chemokine is produced locally by in-
flamed tissues and is a potent activator of eosinophils and
basophils (26, 31, 43). Moreover, eotaxin-deficient mice show
an impaired allergen-induced eosinophil infiltration in the
lungs (48), and eotaxin has a role in the growth of granulocytic
progenitors and in the differentiation of embryonic mast cell
progenitors (45).
Eotaxin is a selective ligand for CCR3, while its other ago-
nists, RANTES, eotaxin-2, and MCP-2, -3, and -4 (19, 42, 56),
are also able to bind other chemokine receptors. CCR3 is
mostly expressed by eosinophils, basophils (42, 56), and Th2
lymphocytes (50) that are recruited at sites of allergic inflam-
mation; therefore, this ligand-receptor pair is crucially involved
in the generation of allergic reactions, antihelminth responses
and, potentially, the modulation of responses after other in-
fections.
Examples of virus-host interactions have been described for
several classes of viruses and, in particular, several viral ORFs
encode for chemokines and chemokine receptors. This sug-
gests strongly that these molecules may possess important reg-
ulatory functions for viral escape from, or interaction with,
immune responses (2, 16, 22).
Human CMV (37) encodes four potential chemokine recep-
tors: UL33, UL78, US27, and US28. US28 is a functionally
active molecule (20, 41), and it has been recently shown that its
expression may alter chemokine levels in the supernatant of
infected cells, possibly by a sequestration mechanism (12),
potentially affecting immune responses, cellular proliferation
and, ultimately, the course of viral infection. UL33, conserved
in murine and rat CMV (M33 and R33, respectively) encodes
a chemokine receptor-like molecule that, when mutated, does
not affect viral replication in tissue culture but is important for
murine and rat CMV replication in salivary glands, suggesting
a potential role of this receptor in viral tropism (9, 17, 35).
Poxviruses provide additional evidence for the importance
of chemokines in controlling viral spread through the identifi-
cation of distinct viral mechanisms for interfering with chemo-
kine function. Examples are represented by a chemokine ho-
molog encoded by molluscum contagiosum virus (MC148R),
functional as an antagonist for several chemokines (32), and
myxoma virus MT-7, a low-affinity chemokine-binding protein
that interacts with the heparin-binding domain of chemokines,
thereby potentially disrupting their normal association with the
extracellular matrix (33). Similarly, the vCKBP protein of the
T1/35K family, expressed by myxoma, vaccinia, cowpox and
camelpox viruses, binds to CXC, C, and CC chemokines,
thereby blocking their interaction with chemokine receptors
(5, 24). Functions of vCKBP have been demonstrated, namely,
the inhibition of eotaxin-induced eosinophil infiltration in an in
vivo model of allergic inflammation and the inhibition of leu-
kocyte recruitment to foci of rabbitpox virus infection (24).
Our demonstration of a functional activity of the EHV-2 E1
ORF indicates that this virally encoded chemokine receptor
may play a role in the subversion of immune functions during
EHV-2 infection. Possible functions include the sequestration
of cellular chemokines at sites of infection, the modulation of
virus replication in the presence of secreted chemokines, or the
altered trafficking of virus-infected cells in response to chemo-
kine gradients. Elucidation of the biological significance of E1
during virus infection may be achieved through characteriza-
tion of mutant EHV-2 viruses with the E1 ORF deleted,
thereby determining the influence of E1 upon virus replication
and tissue tropism in vitro and in vivo.
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